Evaluation of efficacy and safety of Lactobacillus rhamnosus in children aged 4–48 months with atopic dermatitis: An 8-week, double-blind, randomized, placebo-controlled study

Wu, Yijie; Wu, Wei; Hung, Chia-Wei; Ku, Ming-Shiu; Liao, Pei-Fen; Sun, Hai-Lun; Lu, Ko-Hsiu; Sheu, Ji-Nan; Ko, Jiunn‐Liang

doi:10.1016/j.jmii.2015.10.003

Cited by 40 publications

(34 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eight trials [ 33 – 37 , 39 , 41 , 43 ] reported the drop out in both intervention group and control group, and only four trials [ 33 , 39 , 41 , 43 ] used intention-to-treat (ITT) to analyze for all outcome [ 33 , 39 , 41 ] and primary outcome [ 43 ], and the other four trials [ 34 – 37 ] analyzed data by per-protocol (PP) and reported the data of available participants. Besides, two trials [ 39 , 41 ] analyzed by both ITT and PP. We considered one trial [ 34 ] as high risk of incomplete data for loss to follow up without ITT analysis because of 13 withdrawals in intervention group and 16 withdrawals in control group among the 100 participants in the trial.…”

Section: Resultsmentioning

confidence: 99%

“…We considered one trial [ 34 ] as high risk of incomplete data for loss to follow up without ITT analysis because of 13 withdrawals in intervention group and 16 withdrawals in control group among the 100 participants in the trial. Four trials [ 33 , 39 , 41 , 43 ] were considered as low risk of bias and the others as unclear. Eleven trials [ 21 , 25 , 29 , 33 , 35 – 37 , 40 – 43 ] mentioned non-commercial funding.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Complementary and alternative medicine for treatment of atopic eczema in children under 14 years old: a systematic review and meta-analysis of randomized controlled trials

Liu

Stub

Kristoffersen

et al. 2018

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundDue to limitations of conventional medicine for atopic eczema (AE), complementary and alternative medicine (CAM) is widely used as an alternative, maintaining, or simultaneous treatment for AE. We aimed to evaluate the beneficial and harmful effects of CAM for children with AE under 14 years old.MethodsWe searched for randomized trials on CAM in 12 Chinese and English databases from their inception to May 2018. We included children (< 14 years) diagnosed with AE, who received CAM therapy alone or combined with conventional medicine. We extracted data, and used the Cochrane “Risk of bias” tool to assess methodological quality. Effect was presented as relative risk (RR) or mean difference (MD) with 95% confidence interval (CI) using RevMan 5.3.ResultsTwenty-four randomized controlled trials involving 2233 children with AE were included. Methodological quality was of unclear or high risk of bias in general. The trials tested 5 different types of CAM therapies, including probiotics, diet, biofilm, borage oil, and swimming. Compared to placebo, probiotics showed improved effect for the SCORAD index (MD 9.01, 95% CI 7.12–10.90; n = 5). For symptoms and signs such as itching, skin lesions, CAM combined with usual care was more effective for symptom relief ≥95% (RR 1.47, 95% CI 1.30–1.68; n = 8), and for ≥50% symptoms improvement (RR 1.34, 1.25–1.45; n = 9) compared to usual care. There was no statistic significant difference between CAM and usual care on ≥95% improvement or ≥ 50% improvement of symptoms. However, swimming, diet and biofilm showed improvement of clinical symptoms compared with usual care. At follow-up of 8 weeks to 3 years, CAM alone or combined with usual care showed lower relapse rate (RR 0.38, 0.28–0.51, n = 2; RR 0.31, 0.24–0.40, n = 7; respectively) compared to usual care. Twelve out of 24 trials reported no occurrence of severe adverse events.ConclusionsLow evidence demonstrates that some CAM modalities may improve symptoms of childhood AE and reduce relapse rate. Safety remains unclear due to insufficient reporting. Further well-designed randomized trials are needed to confirm the potential beneficial effect and to establish safety use.Electronic supplementary materialThe online version of this article (10.1186/s12906-018-2306-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Complementary and alternative medicine for treatment of atopic eczema in children under 14 years old: a systematic review and meta-analysis of randomized controlled trials

Liu

Stub

Kristoffersen

et al. 2018

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…Indeed, cytokine profiles in co-cultures of the probiotic bacteria with PBMCs show considerable variations between species and strains. Among probiotic species, a lot of reports indicate that even different strains of Lactobacillus have various impact on the severity of AD when were administered to children [28,29].…”

Section: Discussionmentioning

confidence: 99%

Lactobacilus Delbrueckii subsp. Bulgaricus Modulates the Secretion of Th1/Th2 and Treg Cell-Related Cytokines by PBMCs from Patients with Atopic Dermatitis

Sheikhi

Giti²,

Heibor

et al. 2017

Drug Res (Stuttg)

View full text Add to dashboard Cite

Atopic dermatitis (AD) is an inflammatory skin disease which may be due to the imbalance between Th1-, Th2 and Treg cell-related immune responses. Evidences suggest that appropriate stimulation with probiotics may correct the skewed immune response in children with AD. The aim was to determine the effects of the yogurt culture on the secretion of Th1/Th2/Treg type cytokines by PBMCs from children with AD. was cultivated on MRS broth. The PBMCs from 20 children with AD were separated by Ficoll-Hypaque centrifugation and co-cultured with different concentrations of UV killed bacteria in RPMI-1640 plus 10% FCS for 48/72 h. The levels of IL-10, IL-4, IL-12 and IFN-γ were measured in supernatant of PBMCs by ELISA. significantly up-regulated the secretion of IL-10, IL-12 and IFN-γ, whereas decreased the secretion of IL-4 by PBMCs at both incubation times 48 h/72 h and both bacteria:PBMCs ratios 100:1/50:1, compared to control (p<0.05). There were no significant differences between incubation times 48 h and 72 h regarding the secretion levels of IL-12, IFN-γ and IL-4. However, the secretion of IL-10 by -stimulated PBMCs at incubation time 72 h and in the presence of bacteria:PBMCs ratio 100:1 was significantly higher than in incubation time 48 h and in the presence of bacteria:PBMCs ratio 50:1 (P<0.000 and P<0.00, respectively). These data show that may modulate the secretion of Th1-, Th2-Treg-related cytokines in AD patients. Therefore, the possible potential therapeutic of for treatment of AD should be consider in further investigation.

show abstract

“…31 However, some effects may be strain or species specific, as probiotics with Lactobacillus rhamnosus and Lactobacillus paracasei have yielded mixed results. [32][33][34][35][36] Thus far, few studies have utilized live bacteria in topical probiotics for treatment of AD. Nakatusji et al recently demonstrated that topical application of commensal skin bacteria protects against pathogens.…”

Section: Atopic Dermatitismentioning

confidence: 99%

Changing our microbiome: probiotics in dermatology

et al. 2019

View full text Add to dashboard Cite

Summary Background Commensal bacteria are a major factor in human health and disease pathogenesis. Interest has recently expanded beyond the gastrointestinal microbiome to include the skin microbiome and its impact on various skin diseases. Objectives Here we present current data reviewing the role of the microbiome in dermatology, considering both the gut and skin microflora. Our objective was to evaluate whether the clinical data support the utility of oral and topical probiotics for certain dermatological diseases. Methods The PubMed and ClinicalTrials.gov databases were searched for basic science, translational research and clinical studies that investigated differences in the cutaneous microbiome and the impact of probiotics in patients with atopic dermatitis, acne vulgaris, psoriasis, chronic wounds, seborrhoeic dermatitis and cutaneous neoplasms. Results Few clinical trials exist that explore the utility of probiotics for the prevention and treatment of dermatological diseases, with the exception of atopic dermatitis. Most studies investigated oral probiotic interventions, and of those utilizing topical probiotics, few included skin commensals. In general, the available clinical trials yielded positive results with improvement of the skin conditions after probiotic intervention. Conclusions Oral and topical probiotics appear to be effective for the treatment of certain inflammatory skin diseases and demonstrate a promising role in wound healing and skin cancer. However, more studies are needed to confirm these results. What's already known about this topic? The microbiome plays a role in human health and disease pathogenesis. Probiotics can manipulate the host microbiome and may confer health benefits for patients. Research to date has already begun to explore the utility of oral and topical probiotics for certain dermatological diseases. What does this study add? This review presents basic science and clinical trial data to support the role of the gut and skin microbiome in dermatology. Current data are reviewed on the use of probiotics in the prevention and treatment of skin diseases, including atopic dermatitis, acne vulgaris, psoriasis, seborrhoeic dermatitis, chronic wounds and cutaneous neoplasms. Future probiotic interventions are proposed.

show abstract

Evaluation of efficacy and safety of Lactobacillus rhamnosus in children aged 4–48 months with atopic dermatitis: An 8-week, double-blind, randomized, placebo-controlled study

Cited by 40 publications

References 34 publications

Complementary and alternative medicine for treatment of atopic eczema in children under 14 years old: a systematic review and meta-analysis of randomized controlled trials

Complementary and alternative medicine for treatment of atopic eczema in children under 14 years old: a systematic review and meta-analysis of randomized controlled trials

Lactobacilus Delbrueckii subsp. Bulgaricus Modulates the Secretion of Th1/Th2 and Treg Cell-Related Cytokines by PBMCs from Patients with Atopic Dermatitis

Changing our microbiome: probiotics in dermatology

Contact Info

Product

Resources

About